The AstraZeneca's US BioPharma Respiratory and Immunology (R&I) Team holds a unique position in respiratory disease, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), with a range of differentiated potential medicines in development by using novel combinations, biologics and devices. Capitalize on formulary approvals and other opportunities through effective implementation of the Strategic Targeting Plans by using a wide variety of promotional, personnel resources and analytical tools to enhance effectiveness in assigned sales territory, based on local assessment of customer needs.